Walvax Biotechnology Co., Ltd. (300142.SZ)
CNY 10.87
(-1.0%)
CNY 10.87
(-1.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 938.22 Million CNY | -39.54% |
| 2022 | 1.35 Billion CNY | 48.43% |
| 2021 | 865.89 Million CNY | -5.74% |
| 2020 | 1.5 Billion CNY | 325.01% |
| 2019 | 341.87 Million CNY | -79.84% |
| 2018 | 1.34 Billion CNY | 610.09% |
| 2017 | -341.68 Million CNY | -192.35% |
| 2016 | 288.34 Million CNY | 665.02% |
| 2015 | -642.3 Million CNY | -110.03% |
| 2014 | 440.18 Million CNY | 119.85% |
| 2013 | 206.81 Million CNY | -29.84% |
| 2012 | 330.32 Million CNY | 20.6% |
| 2011 | 265.19 Million CNY | 37.73% |
| 2010 | 199.28 Million CNY | 73.12% |
| 2009 | 109.1 Million CNY | 90.43% |
| 2008 | 53.42 Million CNY | 318.68% |
| 2007 | 11.58 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 213.54 Million CNY | 98.86% |
| 2024 Q3 | 98.61 Million CNY | -69.57% |
| 2024 Q1 | 162.95 Million CNY | 1121.99% |
| 2023 Q2 | 491.79 Million CNY | 122.84% |
| 2023 Q1 | 220.69 Million CNY | -33.35% |
| 2023 Q3 | 213.1 Million CNY | -56.67% |
| 2023 Q4 | 13.33 Million CNY | -93.74% |
| 2023 FY | - CNY | -39.54% |
| 2022 FY | - CNY | 48.43% |
| 2022 Q1 | 167.22 Million CNY | -41.61% |
| 2022 Q3 | 370 Million CNY | -28.34% |
| 2022 Q2 | 516.32 Million CNY | 208.77% |
| 2022 Q4 | 331.11 Million CNY | -10.51% |
| 2021 Q4 | 286.39 Million CNY | 29.61% |
| 2021 Q1 | 122.4 Million CNY | -78.69% |
| 2021 Q2 | 337.76 Million CNY | 175.95% |
| 2021 Q3 | 220.97 Million CNY | -34.58% |
| 2021 FY | - CNY | -5.74% |
| 2020 Q1 | -17.79 Million CNY | -212.78% |
| 2020 Q2 | 138.33 Million CNY | 877.42% |
| 2020 FY | - CNY | 325.01% |
| 2020 Q3 | 360.15 Million CNY | 160.34% |
| 2020 Q4 | 574.38 Million CNY | 59.48% |
| 2019 Q2 | 90.55 Million CNY | 181.65% |
| 2019 FY | - CNY | -79.84% |
| 2019 Q1 | 32.15 Million CNY | -97.03% |
| 2019 Q3 | 62.29 Million CNY | -31.21% |
| 2019 Q4 | 15.77 Million CNY | -74.67% |
| 2018 Q1 | 2.15 Million CNY | 100.52% |
| 2018 FY | - CNY | 610.09% |
| 2018 Q3 | 49.83 Million CNY | -47.84% |
| 2018 Q4 | 1.08 Billion CNY | 2075.47% |
| 2018 Q2 | 95.54 Million CNY | 4324.48% |
| 2017 Q3 | 20.87 Million CNY | 96.55% |
| 2017 FY | - CNY | -192.35% |
| 2017 Q1 | -15.12 Million CNY | -106.55% |
| 2017 Q2 | 10.61 Million CNY | 170.21% |
| 2017 Q4 | -416.78 Million CNY | -2096.91% |
| 2016 Q3 | -50.8 Million CNY | 9.7% |
| 2016 FY | - CNY | 665.02% |
| 2016 Q1 | 9.08 Million CNY | 104.49% |
| 2016 Q4 | 230.91 Million CNY | 554.52% |
| 2016 Q2 | -56.25 Million CNY | -719.29% |
| 2015 Q2 | 38.82 Million CNY | 264.62% |
| 2015 FY | - CNY | -110.03% |
| 2015 Q4 | -202.34 Million CNY | -463.45% |
| 2015 Q3 | 55.67 Million CNY | 43.4% |
| 2015 Q1 | -23.58 Million CNY | -105.3% |
| 2014 Q1 | -1.98 Million CNY | -106.81% |
| 2014 Q2 | 16.13 Million CNY | 912.96% |
| 2014 Q3 | -54.18 Million CNY | -435.81% |
| 2014 Q4 | 445.21 Million CNY | 921.62% |
| 2014 FY | - CNY | 119.85% |
| 2013 Q1 | 20.2 Million CNY | -85.56% |
| 2013 Q2 | 95.56 Million CNY | 372.88% |
| 2013 Q3 | -25.51 Million CNY | -126.7% |
| 2013 Q4 | 29.13 Million CNY | 214.18% |
| 2013 FY | - CNY | -29.84% |
| 2012 Q2 | 93.84 Million CNY | 490.92% |
| 2012 Q1 | 15.88 Million CNY | -88.37% |
| 2012 FY | - CNY | 20.6% |
| 2012 Q4 | 139.95 Million CNY | 202.17% |
| 2012 Q3 | 46.31 Million CNY | -50.64% |
| 2011 Q3 | 47.85 Million CNY | -41.92% |
| 2011 Q4 | 136.58 Million CNY | 185.39% |
| 2011 Q1 | 18.45 Million CNY | -73.52% |
| 2011 FY | - CNY | 37.73% |
| 2011 Q2 | 82.4 Million CNY | 346.61% |
| 2010 Q2 | 57.89 Million CNY | 384.37% |
| 2010 FY | - CNY | 73.12% |
| 2010 Q4 | 69.67 Million CNY | 27.18% |
| 2010 Q3 | 54.78 Million CNY | -5.37% |
| 2010 Q1 | 11.95 Million CNY | 0.0% |
| 2009 FY | - CNY | 90.43% |
| 2008 FY | - CNY | 318.68% |
| 2007 FY | - CNY | 0.0% |